Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
  • Home
  • Current Issue
  • Early view
  • Review Series
  • Archive
  • About Us
    About Haematologica Editorial Team Our Policies Advertising Rights & Permissions Contact
  • Haematologica Award
    How to participate 2025 Winners
  • Submit a Manuscript
    Author Guidelines Reviewer Guidelines Submit and Track Manuscript Track Manuscript submitted before October 1st, 2025
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Search articles for: 
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Keyword matches

P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODIES (230 Online Views)

M. Minnema1, H. Fidder2, R. Oostvogels1, V. Biemans2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Gastroenterology, UMC Utrecht, The Netherlands
Multiple Myeloma Colitis Bispecific antibodies

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (207 Online Views)

D. Stoumbos1, A. Antoniou1, K. Lampropoulos1, S. Chrysoglou1, C. Prifti1, M. Panagiotouni1, M. Dadakaridou1, S. Giourgouli2, K. Stefanidis3, M. Kotsopoulou1

1 Metaxa Cancer Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Athens, Greece
2 Metaxa Cancer Hospital, Nuclear Medicine Department, Athens, Greece
3 Metaxa Cancer Hospital, Department of Radiology, Athens, Greece
Multiple Myeloma Elderly Bispecific antibodies
Title matches

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (210 Online Views)

M.C. Vekemans1, O. Rizzo2, N. Meuleman2

1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
2 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium
AL Amyloidosis Multiple Myeloma anti-BCMA

P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS (219 Online Views)

R. Della Pepa1, A. Leone1, L. Esposito1, G.L. D'Elia1, V. Cerbone2, M. Raia2, G. Scalia2, F. Pane1

1 Division of Hematology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy
2 Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE Biotecnologie Avanzate, Naples, Italy

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (206 Online Views)

I. Vigliotta1, A. Varacalli1, M. Talarico1|2, M. Puppi1|2, S. Armuzzi2, B. Taurisano2, I. Pistis1, V. Solli2, V. M. Vuong2, E. Borsi1, A. Vitale1, G. Mazzocchetti3|4, A. Croce2, M. Martello1, A. Poletti2, M. Cavo2, E. Manzato1|2, E. Zamagni1|2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences - University of Bologna, Italy
3 FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy
4 Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy
RRMM CAR-T Circulating plasma cells

P25 | REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB–LENALIDOMIDE–DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES (241 Online Views)

A. Jungova1, M. Stork2, I. Spicka3, J. Radocha4, J. Minarik5, P. Pavlicek6, J. Mihalyova7, L. Pour2, J. Straub3, V. Maisnar4, T. Pika5, T. Dekojova1, J. Soukup6, T. Popkova7, K. Mensikova2, F. Sedlák3, J. Pospiskova4, I. Boichuk2, P. Krhovska5, T. Stopka3, P. Jindra1, T. Jelínek7, Z. Knechtová2, V. Capounova4, V. Latal5, L. Muronova7, A. Heindorfer8, J. Ullrychova9, M. Sykora10, P. Kessler11, R. Hajek7|12

1 Charles University Hospital, Pilsen, Czech Republic
2 University Hospital, Brno, Czech Republic
3 First Faculty of Medicine Charles University, Prague, Czech Republic
4 Charles University Hospital, Hradec Kralove, Czech Republic
5 University Hospital, Olomouc, Czech Republic
6 3rd Faculty of Medicine Charles University Kralovske Vinohrady, Prague, Czech Republic
7 University Hospital, Ostrava, Czech Republic
8 Liberec Regional Hospital, Czech Republic
9 Masaryk Hospital in Usti nad Labem, Czech Republic
10 Hospital Ceske Budejovice, Czech Republic
11 Hospital Pelhrimov, Czech Republic
12 Faculty of Medicine University of Ostrava, Czech Republic
NDMM Multiple Myeloma

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (273 Online Views)

R. Popat1, N.W.C.J. Van De Donk2|3, B. Faiman4, J. Yuda5, K. Kim6, A. Costa7, A. Laheij2|3, R.L. Doty8, J. Omel9, B. Lipe10, L. Sanchez11, A. Chari12, A. Lin13, H. Sroussi14, M. Fernandez15, K.S. Gray15, G. Aguilar15, K. Bolyard15, J. Schultz15, K. Qi15, D. Cortes-Selva15, J. Zhang15, C. Heuck15, K. Hawks15, K. Tian15, M. França15, L. Rasche16

1 University College London Hospitals NHS Foundation Trust, UK
2 Amsterdam University Medical Center, The Netherlands
3 Vrije Universiteit Amsterdam, The Netherlands
4 Cleveland Clinic, USA
5 National Cancer Center Hospital East, Kashiwa, Japan
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 D’or Institute for Research and Education, São Paulo, Brazil
8 University of Pennsylvania Smell and Taste Center, Philadelphia, USA
9 The Central Nebraska Myeloma Support Group, Grand Island, USA
10 University of Rochester Medical Center, USA
11 Icahn School of Medicine at Mount Sinai, New York, USA
12 University of California, San Francisco, USA
13 University of Pennsylvania, Philadelphia, USA
14 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA
15 Johnson & Johnson
16 University Hospital of Würzburg, Germany
TALISMAN study Multiple Myeloma RRMM
Text matches

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (221 Online Views)

First match: ... ill be used in cytotoxicity assays with novel T-cell-based therapies, including bispecific antibodies and CAR T cells. Conclusions. We established and functionally valida ...

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model

P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS (253 Online Views)

First match: ... ). At baseline, patients received steroids (61.2%), anti-plasma cell monoclonal antibodies (49.3%), immunomodulatory drugs (46.3%), proteasome inhibitors (28.4%) and bisp ...

E. Kastritis1, S. Sánchez-Ramón2, A.G. Szabo3, B. Machalinski4, A. Pérez-Montaña5, J. Chen6, B. Mc Coy7, M. Kamieniak6, S. Wietek7

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
2 Department of Clinical Immunology, Institute of Laboratory Medicine, Hospital Clínico San Carlos, Complutense University of Madrid, Spain
3 Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark
4 Department of Hematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
5 Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
6 Takeda Development Center Americas, Inc, Cambridge, USA
7 Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Multiple Myeloma HyMMy Trial Secondary immunodeficiency

P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE (189 Online Views)

First match: ... abilize, likely reflecting the impact of novel drugs. Sixteen patients received bispecific antibodies across multiple lines (second to tenth); in this subgroup, median pr ...

G. Giunta1, C. Bellofiore2, E. Scalisi1, V. Del Fabro3, F. Elia1|2, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo1|2, A. Romano1|2, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
3 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
Multiple myeloma Real-World Practice Sicily

P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE (264 Online Views)

First match: ... ential integration of immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cellular therapies, and bispecific antibodies, has significantly improved surv ...

G. Giunta1, C. Bellofiore2, E. Scalisi1, F. Elia2|1, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo2|1, A. Romano2|1, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy

B05 | SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE (266 Online Views)

First match: ... effectiveness of CD38-targeted and immune-mediated therapies (such as CAR-T and bispecific antibodies) in EMD. Although larger studies are needed to confirm these finding ...

V. Desantis1, A. Andriano1, G. De Martino1, T. Düking2, O. Hartwig2, G. Ingravallo3, M. Biondo3, C. Botta4, R. Ria5, A. Vacca5, A.G. Solimando5

1 Department of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, Italy
2 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
3 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Italy
4 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
5 Internal Medicine "Guido Baccelli", University of Bari Aldo Moro, Italy
Spatial Imaging Plasma Cell Subclones Multiple Myeloma.

B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT (349 Online Views)

First match: ... ing number of patients are presenting with disease refractory to CD38-targeting antibodies, two immunomodulatory drugs (IMiDs), two proteasome inhibitors (PIs), as well a ...

C. Riedhammer1, M. Truger2, H. Lee3, L.B. Leypoldt4|5, M. Meggendorfer2, S. Hutter2, H. Müller2, J. Mersi1, S.K. Kadel1, T. Buchwald1, R. Kosch4, M. Helal6, N. Afrin6, A. Rosenwald7, E. Gerhard-Hartmann7, A. Brioli8|9, J. Krönke8, T. Haferlach2, C. Haferlach2, K.C. Weisel4, P. Neri3, H. Einsele1, K.M. Kortüm1, J.M. Waldschmidt1, N. Bahlis3, N. Weinhold10|11, L. Rasche1|6

1 Department of Internal Medicine 2, University Hospital of Würzburg, Germany
2 MLL Munich Leukemia Laboratory, Germany
3 Arnie Charbonneau Cancer Institute, University of Calgary, Canada
4 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany
5 Mildred Scheel Early Career Center, University Medical Center Hamburg-Eppendorf, Germany
6 Mildred Scheel Early Career Center, University Hospital Würzburg, Germany
7 Institute of Pathology, University of Würzburg, Germany
8 Department of Internal Medicine C, University Hospital of Greifswald, Germany
9 Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
10 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Germany
11 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center, Germany
Multiple myeloma Hepta-refractory Immunotherapy.

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (347 Online Views)

First match: Background. CAR T-cells and bispecific antibodies (BsAbs) (T cell-redirecting therapies, TCRT) have revolutionized the treatment of relapsed/refractory multiple myeloma ( ...

M. Talarico1|2, A. Cattabriga1|3, L. Pagnini1|4, V. Solli1|2, S. Barbato1|2, S. Ghibellini1|2, S. Masci1|2, E. Manzato1|2, M. Puppi1|2, M. Iezza1|2, K. Mancuso1|2, L. Pantani2, P. Tacchetti2, C. Terragna2, M. Ursi5, E. Maffini5, F. Bonifazi5, S. Brocchi3, C. Mosconi1|3, C. Nanni4, S. Fanti1|4, E. Zamagni1|2

1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
3 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
4 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
RRMM Functional Imaging T-cell Therapy

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (211 Online Views)

First match: Introduction. Teclistamab is the first approved BCMA×CD3 bispecific antibody for treating triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) with ≥20, ...

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL (286 Online Views)

First match: ... on and tracking of patient-specific M-proteins, discrimination from therapeutic antibodies, and accurate quantification below the detection limits of conventional serum p ...

J.X. Jin1, V.R. Ginde2, S. Huhn1|3, P.. Reichert1|3, U. Bertsch1|3, R. Fenk4, B. Besemer5, A. Boquoi6, R. Schroers7, I. Von Metzler8, M. Hänel9, C.. Mann10, L.B. Leypoldt11, B. Heilmeier12, C. Scheid13, T. Peters-Regehr14, I.W. Blau15, C. Müller-Tidow1, S. Luntz16, T.A.W. Holderried17, K. Trautmann-Grill18, D. Gezer19, M. Klaiber-Hakimi20, M. Müller21, E. Shumilov22, W. Knauf23, C.S. Michel24, T. Geer25, H. Riesenberg26, C.. Lutz27, M.S. Raab1, N. Weinhold1, M. Hoffmann28, A. Benner2, P. Findeisen29, K.C. Weisel11, H.J. Salwender30, H. Goldschmidt1|3, E.K. Mai1

1 Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group GMMG, Heidelberg University Hospital and Medical Faculty Heidelberg, Germany
2 Division of Biostatistics, German Cancer Research Center
3 National Center for Tumor Diseases Heidelberg, Germany
4 Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Germany
5 Department of Internal Medicine II, University Hospital Tübingen, Germany
6 Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Germany
7 Department of Hematology and Oncology, Knappschaft Kliniken, Ruhr-University Bochum, Germany
8 Department of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
9 Department of Internal Medicine III, Klinikum Chemnitz, Germany
10 Department for Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, Marburg, Germany
11 Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Germany
13 Department of Internal Medicine I, University Hospital Cologne, Germany
14 The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany
15 Medical Clinic, Charité University Medicine Berlin, Germany
16 Coordination Centre for Clinical Trials-KKS, University Hospital and Medical Faculty Heidelberg, Germany
17 Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Germany
18 Department of Internal Medicine I, University Hospital Dresden, Germany
19 Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Germany
20 Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Germany
21 Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Germany
22 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
23 Center for Hematology and Oncology Bethanien, Frankfurt am Main, Germany
24 Department of Internal Medicine III, University Hospital Mainz, Germany
25 Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany
26 Hematology/Oncology Center, Bielefeld, Germany
27 Hematology/Oncology Center, Koblenz, Germany
28 Medical Clinic A, Clinic Ludwigshafen, Germany
29 MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany
30 Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Germany. °For The German-Speaking Myeloma Multicenter Group. *Contributed equally as senior authors. *Hd7 Investigators
MALDI-TOF Minimal Residual Disease Multiple Myeloma

P65 | FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN THE ANTI-CD38 QUADRUPLET ERA: REDEFINITION THROUGH REAL WORLD DATA (232 Online Views)

First match: ... uction upfront of quadruplet regimens (QUAD) incorporating anti-CD38 monoclonal antibodies (mAb) has led to a substantial outcome benefit, particularly in ASCT eligible ( ...

S. Morè1|2, M. Offidani2, L. Corvatta3, T. Za4, F. Fazio5, M. Gherardini5, V. Bongarzoni6, B. Anaclerico6, L. Franceschini7, S. Ferraro8, L. Cupelli8, R. Spadano9, L. De Padua10, A. Rago11, S. Gentili12, R. Latagliata13, M. Garzia14, I. Cordone15, V. Mezzanotte7, E. Rossi4, F. Di Landro4, Z. Limongi5, E. Morsia1, A. Poloni1, M.T. Petrucci5

1 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
2 Hematology Clinic, AOU delle Marche, Ancona, Italy
3 Internal Medicine, Ospedale E. Profili, Fabriano, Italy
4 Hematology Clinic, Policlinico Agostino Gemelli, Rome, Italy
5 Hematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy
6 Department of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy
7 Lymphoproliferative Diseases Unit, Tor Vergata University Hospital, Rome, Italy
8 Hematology, Ospedale Sant’Eugenio, Rome, Italy
9 Hematology Unit, Pescara Hospital, Italy
10 UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, Frosinone, Italy
11 UOSD Ematologia ASL Roma1, Italy
12 UOSD Ematologia Civitanova Marche AST Macerata, Italy
13 UOC Hematology, Santa Rosa Hospital, Viterbo, Italy
14 Department of Hematology, Hematology San Camillo Forlanini Hospital, Rome, Italy
15 IRCCS Istituto Nazionale Tumori Regina Elena- Dipartimento di Ricerca, Diagnostica Avanzata ed Innovazione Tecnologica-IFO, Rome, Italy
Functional high-risk NDMM Multiple Myeloma

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (271 Online Views)

First match: ... with relapsed/refractory disease. Tec, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has demonstrated deep and durable responses in multiple myeloma (MM). ...

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial

P03 | BONE MARROW MICROENVIRONMENT-DEPENDENT INDUCTION OF mTORC1 CAUSES THERAPY RESISTANCE IN MULTIPLE MYELOMA (262 Online Views)

First match: ... -conditioned medium. Candidate genes are now being validated using neutralizing antibodies, CRISPR editing, and pharmacological inhibition. Future work will define their ...

M.H. Janssens1, G. De Wilde1, M. Spaargaren1, R.W. Groen2, J.E.J. Guikema1

1 Pathology, Amsterdam UMC, The Netherlands
2 Hematology, Amsterdam UMC, The Netherlands
mTORC1 FOXO transcription factors Rapamycin.

P05 | ZEBULARINE MODULATES DNA METHYLTRANSFERASE EXPRESSION THROUGH ASSOCIATED HISTONE COMPLEXES AT THEIR PROMOTERS IN MULTIPLE MYELOMA CELL LINES (287 Online Views)

First match: ... were treated with 250 μM zebularine, and chromatin was immunoprecipitated using antibodies against H3K9me3, H3K36me2, H3K36me3, and H3K4me3. The enrichment of these histo ...

L. Slavíčková1, D. Švehlová1, J. Minarik2|3, K. Smešný Trtková1|4|5

1 Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
2 Department of Hemato-oncology, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
3 Department of Hemato-oncology, University Hospital Olomouc, Czech Republic
4 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
5 Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Czech Republic
Zebularine DNA methylation Multiple Myeloma.

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (252 Online Views)

First match: Background. Cevostamab is a FcRH5xCD3 T-cell-engaging bispecific antibody that has shown promising activity and manageable safety as monotherapy in pts with late-line RRM ...

R. Popat1, S. Harrison2, C. H. Riley3, H.S. Mian4, A. Spencer5, N. Lavi6, L. Paris7, T. Jelínek8, M. Szarejko9, S. Grosicki10, K. Kim11, I. Sandhu12, S. Chebon13, T. Tyagi14, P. Sewpaul15, L. Richardson15, K. Trunzer13, A. Mishra14, S. Trudel16

1 University College London Hospitals NHS Foundation Trust, UK
2 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University and The Royal Melbourne Hospital, Australia
3 Rigshospitalet, Copenhagen, Denmark
4 McMaster University, Hamilton, Canada
5 Alfred Health-Monash University, Melbourne, Australia
6 Rambam Health Care Campus, Haifa, Israel
7 ASST Papa Giovanni XXIII, Bergamo, Italy
8 Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Czech Republic
9 Medical University of Gdansk, Poland
10 Medical University of Silesia, Katowice, Poland
11 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
12 Cross Cancer Institute, University of Alberta, Edmonton, Canada
13 F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Genentech, Inc, South San Francisco, USA
15 Roche Products Ltd, Welwyn, UK
16 Princess Margaret Cancer Centre and University of Toronto, Canada
CAMMA 1 study BCMA Multiple Myeloma

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (224 Online Views)

First match: ... AR T) cell therapy, or a neurological evaluation and an electromyography before bispecific antibody (bsAb) therapy. Between 2022 and 2025, 59 pts have received TCRt outsi ...

E. Manzato1|2, M. Puppi1|2, M. Talarico1|2, M. Iezza1|2, S. Masci1|2, S. Ghibellini1|2, A. Vitale2, S. Barbato1|2, P. Tacchetti1, L. Pantani1, K. Mancuso1|2, E. Zamagni1|2

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy
2 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy
Multiple Myeloma Neurological Toxicities RRMM

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (252 Online Views)

First match: Introduction. CAR-T and bispecific antibody treatment for RRMM show promising clinical activity, but most pts relapse. Clinical data indicate that serial and/or prolonged ...

C. Mo1, C. Gasparetto2, C. Costa2, A.J. Cowan3, T. Mark4, Y. Chai4, T. Kashyap4, J. Katz5, M. Amatangelo5, P.G. Richardson1

1 Dana-Farber Cancer Institute, Boston, USA
2 Duke Cancer Institute, Durham, USA
3 University of Washington, Seattle, USA
4 Karyopharm Therapeutics, Newton, USA
5 Bristol Myers Squibb, Princeton, USA
Multiple Myeloma RRMM STOMP trial

P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS (259 Online Views)

First match: Elranatamab (ELRA), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, induced deep and durable responses in BCMA-naïve patients in the registrational MagnetisMM ...

E. Searle1|2, A. Lesokhin3, R. Niesvizky4, B. Arnulf5, S. Larson6, C.. Strouse7, C. Fernandez De Larrea8, D. Vesole9, Y. Nagai10, S.T. Sullivan11, E. Leip11, N. Bahlis12

1 The Christie NHS Foundation Trust, Manchester, UK
2 University of Manchester, UK
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Weill Cornell Medicine/New York Presbyterian Hospital, USA
5 Hôpital Saint-Louis, APHP, Université Paris, France
6 UCLA Medical Center, Santa Monica, USA
7 Carver College of Medicine,Iowa City, USA
8 Hospital Clínic, Barcelona, Spain
9 John Theurer Cancer Center, Hackensack, USA
10 Kobe City Medical Center General Hospital, Japan
11 Pfizer Inc, Cambridge, USA
12 Arnie Charbonneau Cancer Institute, Calgary, Canada
RRMM BCMA MagnetisMM-3

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (248 Online Views)

First match: Introduction. Teclistamab is a first-in-class CD3xBCMA-targeting bispecific antibody, indicated for the treatment of triple-class exposed relapsed and refractory multiple ...

N.W.C.J. Van De Donk1, R. Wester2, I. Nijhof3, C. Albrecht4, R. Morano5, C. Entrala6, K. Van Nimwegen1|2|3|4|5|6

1 Amsterdam University Medical Center, The Netherlands
2 Erasmus Medical Center, Rotterdam, The Netherlands
3 St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Johnson & Johnson, Paris, France
5 Johnson & Johnson, Madrid, Spain
6 Johnson & Johnson, Breda, The Netherlands
Multiple Myeloma RRMM Treatment Management
Loading...
Searching...
1 - 25 of 29 items 1 2 > >> 
Navigate
  • Home
  • Current issue
  • Early view
  • Archive
  • About Haematologica
  • Editorial Team
  • Our policies
  • Contact
For Authors
  • Author Guidelines
  • Submit Manuscript
  • Track Manuscript
For Reviewers
  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
For Advertisers
  • Information For Advertising
Education
  • Review Articles
  • Guidelines Articles
Privacy
  • Cookie Policy
  • Newsletter Privacy Policy
  • Privacy Policy
More
  • Rights & Permissions

  • Web design
  • Development
Copyright © 2026 by the Ferrata Storti Foundation | Web design → | Development →
ISSN 0390-6078 print | ISSN 1592-8721 online